In our model, the oral administration of A. actinomycetemcomitans was followed by increased expression of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β), concurrent with reduced expression of barrier proteins (ZO-1 and MUC-2) and alterations in the composition of the intestinal flora in mice with colitis. This evidence concerns the gene MUC2 and colitis.